GSK director Moncef Slaoui to retire
Mr. Slaoui will remain a member of the Board until March 31, 2017. From April 1, 2017 until his retirement, he will serve as an advisor to both GSK and the Board.
Prior to his current role, Mr. Slaoui served as Chairman, GSK R&D for eight years. During his tenure at GSK, Mr. Slaoui has also had responsibility for the franchise commercial organisation, focused on new product launches and lifecycle management. He is a member of the Corporate Executive Team and Board of Directors.
Mr. Slaoui earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was a professor of Immunology at the University of Mons, Belgium.
Mr. Slaoui has authored more than 100 scientific papers and presentations and is a member of the PhRMA Foundation Board of Directors, Advisory Board of Qatar Foundation, National Institutes of Health Advisory Committee to the Director, and the Biotechnology Industry Organization Board of Directors. ■
LATEST MOVES FROM United Kingdom
- BP chairman Carl-Henric Svanberg to retire
- Serco Group COO Ed Casey to leave
- Debenhams appoints David Adams as director
- Cenkos appoints Andrew Boorman to board
- Tristel appoints Tom Jenkins to board
More inside POST